TScan Therapeutics Unveils Presentations at SITC Annual Meeting

Exciting Developments from TScan Therapeutics

TScan Therapeutics, Inc. (NASDAQ: TCRX), based in Waltham, Massachusetts, is a pioneering clinical-stage biotechnology company specializing in T cell receptor (TCR)-engineered T cell therapies. These innovations are aimed at providing advanced treatment options for cancer patients. Recently, TScan announced the acceptance of three significant abstracts that will be presented as posters during the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.

Poster Presentation Highlights

The SITC annual meeting promises to deliver groundbreaking insights into cancer treatment. TScan's research is set to be showcased in three poster presentations, highlighting the company’s commitment to understanding and combating cancer through innovative TCR-T therapy.

Discovery of MAGE-A4-specific TCR-T Therapy Candidate

The first poster will focus on the discovery of a MAGE-A4-specific TCR-T therapy candidate designed for the multiplex treatment of solid tumors. This presentation is authored by a collaborative team including Rutuja Kulkarni, Akshat Sharma, and others. The session is scheduled for Friday, with viewing times from 9:00 a.m. to 7:00 p.m. Central Time at the George R. Brown Convention Center.

Customized TCR-T Cell Therapy Models

The second presentation will delve into preclinical models for T-Plex, a customized multiplexed TCR-T cell therapy that addresses intra-tumor antigen and HLA heterogeneity. Authors Maytal Bowman and Amanda Kordosky lead this insightful research, with their session also set for Friday in the same timeframe and location.

Target Agnostic Platform Development

Finally, the third poster will discuss the development of a target agnostic platform designed to evaluate the reactivity of TCR-engineered T cell therapies to primary human tissues. This session will feature contributions from prominent researchers such as Sveta Padmanabhan and Shubhangi Kamalia. Scheduled for Saturday, the session runs from 9:00 a.m. to 8:30 p.m. Central Time, continuing the tradition of showcasing vibrant research at this significant gathering.

Access to Presentation Materials

For those interested in further details, a copy of the presentation materials will be available in the Publications section of TScan's website after the event concludes. This resource will provide ongoing insights into TScan's research advancements and commitments within the field.

About TScan Therapeutics, Inc.

TScan operates at the frontier of cancer immunotherapy, focusing heavily on the development of TCR-T therapies tailored for various cancer types. Their lead candidates, TSC-100 and TSC-101, are under evaluation for treating patients with hematologic malignancies. These therapies show potential in preventing relapse after allogeneic hematopoietic cell transplantation. Moreover, TScan is triumphantly expanding its ImmunoBank, a repository of TCRs that can recognize a broad range of cancer targets associated with multiple HLA types.

Company Contact Information

For inquiries, Heather Savelle, VP of Investor Relations at TScan, can be reached at 857-399-9840 or via email. Additional communications can be addressed to Maghan Meyers at Argot Partners, with direct contact available through email as well.

Frequently Asked Questions

What is TScan Therapeutics known for?

TScan Therapeutics specializes in developing innovative TCR-engineered T cell therapies aimed at treating cancer.

When is TScan presenting at the SITC Annual Meeting?

TScan will present its posters at the SITC Annual Meeting from November 6 to November 10, with specific sessions on November 8 and 9.

What topics will TScan's presentations cover?

The presentations will explore advancements in TCR-T therapies, including a specific candidate for solid tumors and the development of a target-agnostic platform.

Where can I find the presentation materials after the event?

A copy of the materials will be available in the Publications section of TScan's website after the annual meeting.

How can I contact TScan Therapeutics for more information?

For more information, reach out to Heather Savelle or Maghan Meyers via the provided contact details in the article.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.